These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21857953

  • 1. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.
    Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, Matrisian LM, Brown HA.
    PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953
    [Abstract] [Full Text] [Related]

  • 2. A lipidomic analysis of nonalcoholic fatty liver disease.
    Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ.
    Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
    [Abstract] [Full Text] [Related]

  • 3. Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease.
    Velenosi TJ, Ben-Yakov G, Podszun MC, Hercun J, Etzion O, Yang S, Nadal C, Haynes-Williams V, Huang WA, González-Hódar L, Brychta RJ, Takahashi S, Akkaraju V, Krausz KW, Walter M, Cai H, Walter PJ, Muniyappa R, Chen KY, Gonzalez FJ, Rotman Y.
    Gastroenterology; 2022 Jun; 162(7):1990-2003. PubMed ID: 35283114
    [Abstract] [Full Text] [Related]

  • 4. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, Parker BL, Brown W, Burton P, Watt MJ.
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [Abstract] [Full Text] [Related]

  • 5. A Lipidomic Readout of Disease Progression in A Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.
    Sanyal AJ, Pacana T.
    Trans Am Clin Climatol Assoc; 2015 Sep; 126():271-88. PubMed ID: 26330688
    [Abstract] [Full Text] [Related]

  • 6. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH, Zheng KI, Wang XD, Qiao J, Li YY, Zhang L, Zheng MH, Wu J.
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [Abstract] [Full Text] [Related]

  • 7. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hall Z, Bond NJ, Ashmore T, Sanders F, Ament Z, Wang X, Murray AJ, Bellafante E, Virtue S, Vidal-Puig A, Allison M, Davies SE, Koulman A, Vacca M, Griffin JL.
    Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
    [Abstract] [Full Text] [Related]

  • 8. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Zhou M, Liu X, Wu Y, Xiang Q, Yu R.
    J Ethnopharmacol; 2024 Jul 15; 329():118160. PubMed ID: 38588985
    [Abstract] [Full Text] [Related]

  • 9. A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver.
    Preuss C, Jelenik T, Bódis K, Müssig K, Burkart V, Szendroedi J, Roden M, Markgraf DF.
    Cells; 2019 Mar 22; 8(3):. PubMed ID: 30909521
    [Abstract] [Full Text] [Related]

  • 10. Nonalcoholic fatty liver disease stratification by liver lipidomics.
    Vvedenskaya O, Rose TD, Knittelfelder O, Palladini A, Wodke JAH, Schuhmann K, Ackerman JM, Wang Y, Has C, Brosch M, Thangapandi VR, Buch S, Züllig T, Hartler J, Köfeler HC, Röcken C, Coskun Ü, Klipp E, von Schoenfels W, Gross J, Schafmayer C, Hampe J, Pauling JK, Shevchenko A.
    J Lipid Res; 2021 Mar 22; 62():100104. PubMed ID: 34384788
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, von Schönfels W, Herrmann A, Brückner S, Stickel F, Dufour JF, Chavakis T, Hellerbrand C, Spang R, Maass T, Becker T, Schreiber S, Schafmayer C, Schuppan D, Hampe J.
    Gastroenterology; 2016 Sep 22; 151(3):513-525.e0. PubMed ID: 27318147
    [Abstract] [Full Text] [Related]

  • 12. Concise review of lipidomics in nonalcoholic fatty liver disease.
    Béland-Bonenfant S, Rouland A, Petit JM, Vergès B.
    Diabetes Metab; 2023 May 22; 49(3):101432. PubMed ID: 36781065
    [Abstract] [Full Text] [Related]

  • 13. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
    Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gómez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Noureddin M, Falcón-Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM.
    Gastroenterology; 2017 May 22; 152(6):1449-1461.e7. PubMed ID: 28132890
    [Abstract] [Full Text] [Related]

  • 14. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
    Pathil A, Liebisch G, Okun JG, Chamulitrat W, Schmitz G, Stremmel W.
    Eur J Clin Invest; 2015 Sep 22; 45(9):925-31. PubMed ID: 26108973
    [Abstract] [Full Text] [Related]

  • 15. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
    Ma DW, Arendt BM, Hillyer LM, Fung SK, McGilvray I, Guindi M, Allard JP.
    Nutr Diabetes; 2016 Jul 18; 6(7):e220. PubMed ID: 27428872
    [Abstract] [Full Text] [Related]

  • 16. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
    Sa R, Zhang W, Ge J, Wei X, Zhou Y, Landzberg DR, Wang Z, Han X, Chen L, Yin H.
    J Mol Cell Biol; 2016 Jun 18; 8(3):195-206. PubMed ID: 26993042
    [Abstract] [Full Text] [Related]

  • 17. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.
    Peng KY, Watt MJ, Rensen S, Greve JW, Huynh K, Jayawardana KS, Meikle PJ, Meex RCR.
    J Lipid Res; 2018 Oct 18; 59(10):1977-1986. PubMed ID: 30042157
    [Abstract] [Full Text] [Related]

  • 18. Carboxylesterase 2a deletion provokes hepatic steatosis and insulin resistance in mice involving impaired diacylglycerol and lysophosphatidylcholine catabolism.
    Chalhoub G, Jamnik A, Pajed L, Kolleritsch S, Hois V, Bagaric A, Prem D, Tilp A, Kolb D, Wolinski H, Taschler U, Züllig T, Rechberger GN, Fuchs C, Trauner M, Schoiswohl G, Haemmerle G.
    Mol Metab; 2023 Jun 18; 72():101725. PubMed ID: 37059417
    [Abstract] [Full Text] [Related]

  • 19. Aging exacerbates high-fat diet-induced steatohepatitis through alteration in hepatic lipid metabolism in mice.
    Ishizuka K, Kon K, Lee-Okada HC, Arai K, Uchiyama A, Yamashina S, Yokomizo T, Ikejima K.
    J Gastroenterol Hepatol; 2020 Aug 18; 35(8):1437-1448. PubMed ID: 32030821
    [Abstract] [Full Text] [Related]

  • 20. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.